postmenopausal osteoporosis
UCB presentation highlights impacts of epilepsy on daily life
The data underlines the consequences of disrupted sleep for patients and caregivers
UCB’s Kygevvi receives positive CHMP opinion for thymidine kinase 2 deficiency
TK2d is an extremely rare disease characterised by severe and progressive muscle weakness
UCB releases new data on Bimzelx for hidradenitis suppurativa
The disease affects around 1% of the population in most studied countries
Amgen agrees to lower prescription drug costs in deal with US government
The company has invested $40bn in US R&D and manufacturing in the past seven years
Amgen reports positive results from landmark cardiovascular study
The study found significant reductions of major cardiovascular events in high-risk adults following treatment
UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome
The study demonstrated a sustained reduction in seizures for patients
Amgen commits $650m to US manufacturing expansion
The investment is expected to generate up to 750 new jobs
Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis
The phase 3 study included around 2,600 patients
Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study
Almost one million new cases of gastric cancer are diagnosed globally every year
UCB shares promising results for fenfluramine in ultra-rare form of epilepsy
CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births
UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials
Approximately 125 million people worldwide are affected by some form of psoriasis
Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD
Immunoglobulin G4-related disease affects approximately 20,000 people in the US